. Author manuscript; available in PMC: 2021 Nov 1.

Published in final edited form as: Transl Res. 2020 May 17;225:82–94. doi: 10.1016/j.trsl.2020.05.003

Table 1:

Specific properties of commercially available fibrinolytic agents

Fibrinolytic agent	Fibrin specificity	Antigenic	Dosing guidelines	Plasma half life (min)	FDA approval
1^st generation
Streptokinase	--	Yes	250,000 units IV over initial 30 minutes, followed by 100,000 units IV infusion per hour for 24 hours	12-20	Yes
Urokinase	--	No	4,400 units/kg IV over the initial 10 minutes, followed by 4,400 units/kg IV infusion per hour for 12 hours	7-20	Yes
2^nd generation
Alteplase	++	No	100 mg IV infusion over 2 hours	4-8	Yes
3^rd generation
Tenecteplase	+++	No	Single weight-adjusted IV bolus injection over 5 to 10 seconds	15-24	No
Reteplase	+	No	Two IV bolus injections of 10 units each, administered 30 minutes apart	11-19	No